The Supreme Court in a 9-0 ruling invalidated Myriad's patents on BRCA opening up the field for cheaper testing for the breast cancer risk genes BRCA1 and BRCA2. Myriad was criticized for selling $3000 tests and blocking mon-n-pop University labs to run similar tests at fraction of the cost.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label patent. Show all posts
Showing posts with label patent. Show all posts
Thursday, June 13, 2013
Subscribe to:
Posts (Atom)